No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
178 |
4. Check minimum number of eventsNone |
178 |
5. Include endpointsNone |
178 |
6. Filter based on genotype QC (FinnGen only) |
176 |
Control definitions (FinnGen only)
- Control exclude
- M13_DORSOPATHY
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M48
- Name in latin
- Fractura vertebrae ex fatigatione
Similar endpoints
↥List of similar endpoints to
Fatigue fracture of vertebra
based on the number of shared cases.
Similar with more cases:
- Spondylopathies
- Dorsopathies
- Diseases of the musculoskeletal system and connective tissue
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1686 | 892 | 789 |
| Only index persons | 1561 | 823 | 738 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.03 | 0.02 |
| Only index persons | 0.03 | 0.03 | 0.03 |
| Median age at first event (years) | |||
| Whole population | 40.97 | 61.05 | 18.09 |
| Only index persons | 40.52 | 60.94 | 17.75 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 176 | 112 | 64 |
| Unadjusted period prevalence (%) | 0.04 | 0.04 | 0.03 |
| Median age at first event (years) | 63.25 | 63.37 | 63.04 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 178
- Matched controls
- 1780
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M48.4
ICD-10 Finland
Fatigue fracture of vertebra
+∞
254.3
177
*
M54.5
ICD-10 Finland
Low back pain
11.5
62.1
106
202
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
19.3
49.3
42
28
M48.0
ICD-10 Finland
Spinal stenosis
70.3
42.0
47
9
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
85.2
41.4
45
7
M54.4
ICD-10 Finland
Lumbago with sciatica
10.8
40.2
51
64
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
8.5
34.4
54
87
N03AX12
ATC
[U] gabapentin; oral
8.3
32.4
51
82
N03AX16
ATC
[U] pregabalin
6.8
31.5
65
139
M54.9
ICD-10 Finland
Dorsalgia, unspecified
9.7
29.8
39
50
M51.3
ICD-10 Finland
Other specified intervertebral disc degeneration
82.4
25.6
28
*
M05BA04
ATC
alendronic acid; oral
6.9
25.6
47
88
M51.1
ICD-10 Finland
Lumbar and other intervertebral disc disorders with radiculopathy
35.1
25.1
32
11
NA3CG
NOMESCO Finland
Lumbar spine extensive MRI examination with high intensity magnet
262.4
23.2
23
*
N02AX02
ATC
tramadol; systemic, rectal
4.4
21.3
94
363
N02AA05
ATC
oxycodone; systemic
4.6
18.5
56
161
M47.2
ICD-10 Finland
Other spondylosis with radiculopathy
199.0
17.9
18
*
S32.0
ICD-10 Finland
Fracture of lumbar vertebra
22.1
17.5
25
13
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
3.6
15.8
87
374
L03
ICPC
Low back symptom/complaint
3.8
14.8
59
204
M05BX04
ATC
denosumab; parenteral
6.4
14.6
26
46
M81.9
ICD-10 Finland
Osteoporosis, unspecified
7.2
14.0
22
34
ABC36
NOMESCO Finland
Decompression of lumbar nerve roots
81.2
13.8
15
*
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
3.3
13.7
88
409
N02BF01
ATC
gabapentin; oral
7.0
13.6
22
35
N06AA09
ATC
amitriptyline; systemic
5.9
13.4
26
50
M80.0
ICD-10 Finland
Postmenopausal osteoporosis with pathological fracture
19.1
12.8
19
11
H05BA01
ATC
calcitonin (salmon synthetic); nasal, parenteral
14.7
12.8
21
16
NA3AD
NOMESCO Finland
Lumbar spine and sacrum CT examination
40.6
12.4
15
*
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
5.7
12.1
24
47
A02BC05
ATC
esomeprazole; systemic
3.0
11.5
82
395
N02AJ06
ATC
codeine and paracetamol; systemic
3.0
11.4
83
404
M80.9
ICD-10 Finland
Unspecified osteoporosis with pathological fracture
19.4
10.9
16
9
N06AX21
ATC
duloxetine; oral
4.7
10.8
27
65
M50.1
ICD-10 Finland
Cervical disc disorder with radiculopathy
63.9
10.8
12
*
NA3EA
NOMESCO Finland
Lumbar spine X-ray examination with flexion
63.9
10.8
12
*
ABC56
NOMESCO Finland
Decompression of lumbar spinal canal and nerve roots
+∞
10.5
10
*
M25.5
ICD-10 Finland
Pain in joint
2.9
10.2
65
292
M01AH02
ATC
rofecoxib; oral
3.9
9.9
33
99
M54
ICD-10 Finland
Dorsalgia
4.4
9.8
27
70
L04AX03
ATC
methotrexate; systemic
4.2
9.8
28
75
M01AH01
ATC
celecoxib; oral
3.5
9.5
38
129
M43.0
ICD-10 Finland
Spondylolysis
+∞
9.5
9
*
M03BX02
ATC
tizanidine; oral
2.7
9.3
102
598
P01BA02
ATC
hydroxychloroquine; oral
4.2
9.0
26
70
SPAT1234
SPAT
Support of social functional capacity
5.2
8.8
19
40
M43.1
ICD-10 Finland
Spondylolisthesis
52.6
8.8
10
*
SPAT1229
SPAT
Assessment of need for aid
4.7
8.7
21
49
SPAT1137
SPAT
Taking care of patient’s/customer’s hygiene
4.4
8.6
23
58
M75.1
ICD-10 Finland
Rotator cuff syndrome
2.9
8.6
49
205
N06CA01
ATC
amitriptyline and psycholeptics; systemic
4.3
8.5
23
59
L95
ICPC
Osteoporosis
8.2
8.4
18
24
M47.9
ICD-10 Finland
Spondylosis, unspecified
+∞
8.4
8
*
Z01.8
ICD-10 Finland
Other specified special examinations
2.9
8.4
48
201
M79.6
ICD-10 Finland
Pain in limb
2.5
8.3
82
450
M05BB03
ATC
alendronic acid and colecalciferol; oral
9.6
8.2
16
18
S22.0
ICD-10 Finland
Fracture of thoracic vertebra
12.5
8.2
14
12
M84.3
ICD-10 Finland
Stress fracture, not elsewhere classified
18.2
8.2
12
7
L28
ICPC
Limited function/disability (L)
3.0
8.1
44
178
AA1AD
NOMESCO Finland
CT of head and brain
2.6
7.9
60
290
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
16.0
7.8
12
8
M03BC01
ATC
orphenadrine (citrate); systemic
3.1
7.8
38
145
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
2.9
7.7
44
183
TPH04
NOMESCO Finland
Cathetrisation of vein
2.8
7.6
47
204
NAG62
NOMESCO Finland
Posterior fusion of lumbar spine with fixation, 2-3 vertebraea
83.4
7.5
8
*
G55.1*M51.1
ICD-10 Finland
Compression of nerve roots and nerve plexus in disc diseases in the lumbar region and other regions
83.4
7.5
8
*
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
3.9
7.4
23
65
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
2.9
7.4
39
155
A28
ICPC
Limited function/disability NOS
2.7
7.3
49
221
NH3AA
NOMESCO Finland
Foot and toes X-ray examination
4.0
7.3
22
61
H02AB06
ATC
prednisolone; systemic
2.4
7.2
88
523
R03AC02
ATC
salbutamol; inhalant
2.4
7.1
108
704
X59
ICD-10 Finland
Exposure to unspecified factor
2.8
7.0
41
172
L86
ICPC
Back syndrome with radiating pain
8.8
7.0
14
17
L76
ICPC
Fracture: other
6.6
7.0
17
28
A01
ICPC
Pain general/multiple sites
3.7
7.0
23
68
S32.1
ICD-10 Finland
Fracture of sacrum
41.7
6.8
8
*
B01AB05
ATC
enoxaparin; parenteral
2.4
6.8
62
323
A02BC02
ATC
pantoprazole; systemic
2.4
6.8
117
799
SPAT1254
SPAT
Administration of medicine
2.7
6.7
42
182
SPAT1212
SPAT
Extensive examination of musculoskeletal system
4.0
6.7
20
55
Y83
ICD-10 Finland
Surgical operation and other surgical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
4.1
6.6
19
51
TAC99
NOMESCO Finland
Other blockade for chronic pain
72.3
6.5
7
*
M70.6
ICD-10 Finland
Trochanteric bursitis
3.2
6.5
28
99
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.2
6.4
88
542
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.1
6.4
29
105
H02AB07
ATC
prednisone; oral
3.0
6.4
30
111
SPAT1203
SPAT
Injection therapy, other than intramuscular or subcutaneous
7.5
6.4
14
20
N02AA59
ATC
codeine, combinations excl. psycholeptics; systemic
2.3
6.3
73
419
NAG40
NOMESCO Finland
Anterior fusion of cervical spine without fixation
+∞
6.3
6
*
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
3.2
6.3
27
95
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.6
6.2
41
183
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.2
6.2
72
414
SPAT1220
SPAT
Assessment of need for rehabilitation and/or rehabilitation plan
4.2
6.1
17
44
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
117
702
2.95
10.68
7.5
6.8
1.20
1.22
mmol/l
1.72
107
612
66
311
2.78
9.32
2.6
2.2
—
—
—
0
0
98
573
2.58
8.83
2.8
2.4
78.33
75.03
nmol/l
0.52
90
505
38
142
3.13
8.05
7.4
6.9
12.22
12.93
kpa
0.37
38
137
137
998
2.62
6.95
5.4
3.7
13.80
12.40
mm/h
0.36
126
907
22
70
3.45
5.97
6.7
10.0
93.95
94.93
%
0.45
22
70
116
815
2.22
5.93
10.1
9.8
3.95
3.93
e9/l
0.03
103
717
23
77
3.28
5.77
6.4
9.1
0.62
0.72
%
0.58
23
77
23
77
3.28
5.77
6.3
9.1
1.60
1.25
%
0.62
23
77
136
1031
2.35
5.61
9.6
6.5
80.83
86.15
u/l
0.54
131
955
89
586
2.04
5.14
5.2
4.5
35.33
35.73
g/l
0.28
81
549
91
609
2.01
4.98
3.2
2.3
—
—
—
0
0
77
491
2.00
4.78
4.7
3.2
—
—
—
0
0
47
252
2.18
4.62
1.8
1.6
1126.41
1148.20
nmol/l
0.06
36
188
47
252
2.18
4.62
4.1
3.0
2.46
2.46
mmol/l
0.17
39
225
76
493
1.95
4.41
4.9
3.7
39.00
47.89
ng/l
0.19
53
350
12
24
5.28
4.40
1.4
1.1
—
—
—
0
0
34
162
2.36
4.40
5.7
7.1
104.53
104.62
mmol/l
0.03
34
162
55
320
2.04
4.34
2.4
3.1
4855.12
7734.80
umol/l
0.23
43
283
74
478
1.94
4.34
3.5
2.9
2.33
2.36
mmol/l
1.39
58
427
92
639
1.91
4.33
23.8
12.5
1.21
1.29
inr
0.34
18
198
62
380
1.97
4.21
4.5
3.1
0.20
0.39
e6/l
1.21
54
288
11
23
5.02
3.94
1.5
1.5
—
—
—
0
0
11
23
5.02
3.94
1.5
1.5
—
—
—
0
0
7
8
9.05
3.80
1.3
1.4
—
—
—
0
0
159
1365
2.54
3.80
24.6
13.0
25.93
23.91
mg/l
0.24
134
1038
37
199
2.08
3.55
1.2
1.2
29.35
43.59
iu/ml
—
6
65
17
64
2.83
3.51
1.0
1.2
—
—
—
0
0
37
200
2.07
3.50
2.2
1.8
—
—
—
0
0
28
136
2.26
3.45
1.9
1.7
—
—
—
0
0
13
42
3.26
3.44
1.5
1.4
—
—
—
0
0
21
90
2.51
3.40
1.9
1.6
—
—
—
0
0
6
7
8.81
3.29
2.2
2.7
42.10
266.39
ug/l
—
6
7
75
522
1.75
3.26
2.4
1.9
93.05
93.58
pmol/l
0.03
45
264
59
387
1.78
3.12
3.2
3.8
1824.20
1462.34
ng/l
0.21
49
335
26
134
2.10
2.78
2.0
1.7
—
—
—
0
0
33
188
1.93
2.69
1.4
1.2
7.79
12.41
u/ml
0.21
15
68
8
20
4.14
2.60
1.8
1.7
—
—
—
0
0
22
109
2.16
2.59
2.1
2.5
4.33
5.60
ug/l
0.67
16
95
16
69
2.45
2.57
1.3
1.2
—
—
—
0
0
11
37
3.10
2.54
1.0
1.1
—
—
—
0
0
55
373
1.69
2.52
2.6
2.4
2.77
3.05
mg/l
0.57
48
322
6
12
5.13
2.42
3.3
3.7
—
—
—
0
0
6
12
5.13
2.42
1.3
1.8
12.74
22.91
ug/l
—
6
12
11
39
2.94
2.39
1.0
1.1
—
—
—
0
0
106
856
1.59
2.34
3.3
3.0
—
—
—
0
0
6
13
4.73
2.29
1.7
1.8
—
—
—
0
0
6
13
4.73
2.29
1.7
1.8
—
—
—
0
0
6
13
4.73
2.29
1.7
1.8
—
—
—
0
0
6
13
4.73
2.29
1.7
1.8
—
—
—
0
0
6
14
4.39
2.17
1.7
1.7
—
—
—
0
0
6
14
4.39
2.17
1.7
1.7
—
—
—
0
0
77
589
1.54
2.09
3.3
2.8
112.71
109.41
ug/l
0.06
68
543
36
228
1.73
2.09
3.8
2.8
0.46
1.19
e6/l
1.65
22
134
12
50
2.50
2.07
2.5
1.9
—
—
—
0
0
6
15
4.10
2.05
1.2
1.2
—
—
—
0
0
101
825
1.52
1.99
4.0
3.3
45.37
44.91
u/l
0.03
95
773
17
85
2.11
1.98
1.1
1.3
328.83
193.43
iu/ml
—
6
40
122
1043
1.54
1.90
4.9
3.9
14.67
14.90
pmol/l
0.42
109
935
5
12
4.25
1.83
1.0
1.3
—
—
—
0
0
5
12
4.25
1.83
1.0
1.3
—
—
—
0
0
48
343
1.55
1.73
1.5
1.5
1.42
1.31
u/ml
0.06
13
69
5
13
3.92
1.72
1.0
1.2
—
—
—
0
0
5
13
3.92
1.72
1.0
1.2
—
—
—
0
0
5
13
3.92
1.72
1.0
1.2
—
—
—
0
0
35
232
1.63
1.72
3.9
2.9
1.90
3.14
e6/l
0.56
21
141
5
14
3.64
1.62
2.8
3.6
2.38
4.86
nmol/l
—
5
14
6
20
3.07
1.59
1.2
1.4
—
—
—
0
0
10
44
2.35
1.58
4.9
3.5
3.65
4.05
mmol/l
—
10
44
166
1556
1.99
1.51
33.4
19.7
38.81
39.50
%
0.64
154
1462
44
321
1.49
1.43
2.1
1.5
17.88
20.77
nmol/l
0.69
39
266
157
1459
1.64
1.33
13.7
9.5
22.09
24.49
u/l
1.84
149
1398
77
634
1.38
1.28
4.9
3.7
0.00
0.00
estimate
—
10
135
78
644
1.38
1.27
6.7
5.2
0.00
0.00
estimate
—
9
124
20
125
1.68
1.24
2.9
9.9
24.54
24.98
mmol/l
0.20
20
125
5
19
2.68
1.22
1.2
1.2
—
—
—
0
0
6
26
2.35
1.19
1.2
1.2
55.33
39.12
nmol/l
—
6
26
8
40
2.05
1.13
1.8
1.3
—
—
—
0
0
10
51
2.02
1.13
1.5
1.8
—
—
—
0
0
140
1283
1.43
1.13
6.0
4.6
2.02
1.96
mu/l
0.19
131
1158
7
31
2.31
1.11
1.4
2.3
—
—
—
0
0
5
21
2.42
1.10
1.6
1.7
—
—
—
0
0
5
21
2.42
1.10
1.0
1.1
—
—
—
0
0
14
82
1.77
1.08
6.2
6.3
24.77
25.26
mmol/l
0.21
14
82
14
84
1.72
1.01
1.9
2.9
67.57
56.51
ml/min/173m2
—
7
37
22
150
1.53
0.99
4.1
4.3
31.50
32.90
%
0.28
16
91
9
51
1.80
0.96
1.7
2.4
25.42
16.40
iu/l
—
9
39
0
32
0.00
0.96
0.0
1.1
—
92.17
—
0
6
76
648
1.30
0.94
5.0
3.8
0.00
0.02
estimate
—
8
123
8
45
1.81
0.85
3.4
1.8
—
—
—
0
0
8
45
1.81
0.85
1.4
1.1
—
—
—
0
0
21
148
1.47
0.82
11.0
6.2
—
—
—
0
0
6
33
1.85
0.80
1.5
1.5
—
—
—
0
0
5
24
2.11
0.75
1.2
1.1
—
—
—
0
0
19
134
1.47
0.75
5.8
6.7
9.71
8.43
mmol/l
0.31
19
123
5
93
0.52
0.69
1.0
1.1
—
—
—
0
0
11
71
1.59
0.63
2.5
1.6
—
—
—
0
0
34
275
1.29
0.61
2.6
4.1
23.04
21.25
%
0.17
16
139
8
52
1.56
0.60
3.3
2.0
—
—
—
0
0
34
276
1.29
0.60
1.8
1.7
—
—
—
0
0
41
343
1.25
0.57
4.9
4.7
2.55
3.14
ug/l
0.20
36
309
10
67
1.52
0.51
2.3
7.9
0.79
0.66
%
—
10
67
30
361
0.80
0.49
1.5
1.5
1.14
1.27
mmol/l
0.61
21
300
14
187
0.73
0.48
1.6
1.4
—
—
—
0
0
33
275
1.25
0.48
1.5
1.8
504.86
451.79
pmol/l
0.24
22
224
34
289
1.22
0.42
6.1
3.8
1.02
1.02
kg/l
—
10
48
0
16
0.00
0.41
0.0
1.8
—
—
—
0
0
0
18
0.00
0.40
0.0
1.4
—
—
—
0
0
0
19
0.00
0.39
0.0
1.3
—
—
—
0
0
10
135
0.73
0.38
2.8
2.1
—
—
—
0
0
16
134
1.21
0.24
4.9
3.1
—
—
—
0
0
136
1322
1.12
0.23
4.6
4.8
2.53
2.66
mmol/l
1.02
124
1209
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
157.00
—
0
10
0
12
0.00
0.21
0.0
5.1
—
109.83
—
0
12
6
49
1.23
0.20
1.0
1.2
—
11.46
—
0
11
12
99
1.23
0.20
1.2
1.6
—
—
—
0
0
38
407
0.92
0.15
3.4
3.9
25.81
8.67
mg/mmol
0.43
23
269
9
106
0.84
0.13
4.4
3.4
1.21
1.22
mmol/l
—
9
88
125
1223
1.07
0.13
22.8
12.5
80.29
78.90
ml/min/173m2
0.28
109
977
127
1293
0.94
0.11
4.3
4.3
4.46
4.58
mmol/l
0.58
116
1193
124
1219
1.06
0.09
5.7
5.9
38.90
40.57
mmol/mol
1.41
115
1123
131
1292
1.05
0.08
4.6
4.4
5.73
6.02
mmol/l
1.99
118
1167
6
73
0.82
0.08
1.2
1.6
—
—
—
0
0
125
1232
1.05
0.07
3.9
3.9
1.22
1.23
mmol/l
0.06
115
1121
7
81
0.86
0.07
1.6
1.8
—
—
—
0
0
11
122
0.90
0.07
2.4
1.9
—
—
—
0
0
51
506
1.01
0.00
6.1
3.9
—
—
—
0
0
34
339
1.00
0.00
6.5
3.8
0.00
0.00
estimate
—
8
125
12
123
0.97
0.00
1.9
2.2
1.65
1.46
%
0.41
12
110
128
1282
0.99
0.00
4.4
4.2
1.49
1.50
mmol/l
0.02
118
1172
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
203.00
—
0
5
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint M13_FATIGFRACT and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_FATIGFRACT | 1.518 [1.15, 2.0] | 0.003 |
| Birth year | 0.996 [0.99, 1.0] | 0.403 |
During the follow-up period (1.1.1998 — 31.12.2019), 179 out of 579 females with M13_FATIGFRACT died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_FATIGFRACT | 1.865 [1.31, 2.66] | < 0.001 |
| Birth year | 0.984 [0.97, 0.99] | < 0.001 |
During the follow-up period (1.1.1998 — 31.12.2019), 109 out of 387 males with M13_FATIGFRACT died.
Mortality risk
Mortality risk for people of age
years, who have M13_FATIGFRACT.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.183% | 0.329% |
| 5 | 0.973% | 1.964% |
| 10 | 2.401% | 4.885% |
| 15 | 4.479% | 8.956% |
| 20 | 7.785% | 15.13% |
Relationships between endpoints
↥Index endpoint: M13_FATIGFRACT – Fatigue fracture of vertebra
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data